NASDAQ:FCSCFibrocell Science Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fibrocell Science Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.00 0.00 (0.00 %) (As of 12/13/2019) Add Compare Share Today's Range$3.00Now: $3.00▼$3.0050-Day Range$3.00MA: $3.00▼$3.0052-Week Range$1.45Now: $3.00▼$3.28VolumeN/AAverage Volume78,673 shsMarket Capitalization$29.28 millionP/E RatioN/ADividend YieldN/ABeta1.67 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania.Read More Beat the Market (BTM) Rank™ 1.0 Analyst's Opinion Consensus RatingFibrocell Science has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageFibrocell Science has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesFibrocell Science has received 280 “outperform” votes. (Add your “outperform” vote.)Underperform VotesFibrocell Science has received 274 “underperform” votes. (Add your “underperform” vote.)Community SentimentFibrocell Science has received 50.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote “Outperform” if you believe FCSC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldFibrocell Science does not currently pay a dividend.Dividend GrowthFibrocell Science does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fibrocell Science insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of Fibrocell Science is held by insiders.Percentage Held by Institutions36.72% of the stock of Fibrocell Science is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Fibrocell Science are expected to decrease in the coming year, from $0.10 to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fibrocell Science is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fibrocell Science is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFibrocell Science has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.90 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FCSC Previous Symbol CUSIPN/A CIK357097 Webfibrocell.com Phone484-713-6000Debt Debt-to-Equity Ratio0.47 Current Ratio5.09 Quick Ratio5.09Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio30.00 P/E GrowthN/A Sales & Book Value Annual Sales$350,000.00 Price / Sales83.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book3.06Profitability EPS (Most Recent Fiscal Year)($1.45) Net Income$-10,280,000.00 Net MarginsN/A Return on Equity23.10% Return on Assets10.56%Miscellaneous Employees19 Outstanding Shares9,760,000Market Cap$29.28 million Next Earnings DateN/A OptionableOptionable Receive FCSC News and Ratings via Email Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter. Fibrocell Science (NASDAQ:FCSC) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Fibrocell Science? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fibrocell Science in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Fibrocell Science. How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) announced its quarterly earnings results on Wednesday, August, 14th. The company reported $1.12 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $1.30. The firm had revenue of $21.79 million for the quarter. View Fibrocell Science's earnings history. When did Fibrocell Science's stock split? How did Fibrocell Science's stock split work? Shares of Fibrocell Science reverse split before market open on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 24th 2018. An investor that had 100 shares of Fibrocell Science stock prior to the reverse split would have 20 shares after the split. What price target have analysts set for FCSC? 2 analysts have issued 12 month target prices for Fibrocell Science's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Fibrocell Science's share price to reach $3.00 in the next year. View analysts' price targets for Fibrocell Science. What are Wall Street analysts saying about Fibrocell Science stock? Here are some recent quotes from research analysts about Fibrocell Science stock: 1. According to Zacks Investment Research, "Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. " (11/13/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We are downgrading to Neutral and lowering our price target to $3 from $20 to reflect the valuation offered and accepted by Fibrocell’s management as part of the acquisition terms. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway. Further, until closing, there is no guarantee that the acquisition will close, which could then prompt us to reassess our valuation of Fibrocell." (9/13/2019) Has Fibrocell Science been receiving favorable news coverage? Press coverage about FCSC stock has trended very negative on Thursday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fibrocell Science earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutFibrocell Science. Who are some of Fibrocell Science's key competitors? Some companies that are related to Fibrocell Science include OASMIA PHARMACE/ADR (OASM), Catabasis Pharmaceuticals (CATB), Recro Pharma (REPH), Humanigen (HGEN), ESSA Pharma (EPIX), Galmed Pharmaceuticals (GLMD), Corvus Pharmaceuticals (CRVS), Eton Pharmaceuticals (ETON), Oncolytics Biotech (ONCY), Sesen Bio (SESN), Genprex (GNPX), Catalyst Biosciences (CBIO), TFF Pharmaceuticals (TFFP), CannTrust (CTST) and Aptorum Group (APM). View all competitors. What other stocks do shareholders of Fibrocell Science own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Portola Pharmaceuticals (PTLA), Celldex Therapeutics (CLDX), Inovio Pharmaceuticals (INO), Neos Therapeutics (NEOS), Sorrento Therapeutics (SRNE), Amarin (AMRN), Opko Health (OPK), Verastem (VSTM) and Agile Therapeutics (AGRX). Who are Fibrocell Science's key executives? Fibrocell Science's management team includes the following people: Mr. John Michael Maslowski, Pres, CEO & Director (Age 44)Mr. Sean D. Buckley, VP of Bus. Admin. & Corp. Sec. (Age 37)Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor RelationsMs. Michele Mchugh-Mazzatta, VP of SalesDr. Pierre Compte, Managing Director of Switzerland What is Fibrocell Science's stock symbol? Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC." What is Fibrocell Science's stock price today? One share of FCSC stock can currently be purchased for approximately $3.00. How big of a company is Fibrocell Science? Fibrocell Science has a market capitalization of $29.28 million and generates $350,000.00 in revenue each year. The company earns $-10,280,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Fibrocell Science employs 19 workers across the globe. What is Fibrocell Science's official website? The official website for Fibrocell Science is fibrocell.com. How can I contact Fibrocell Science? Fibrocell Science's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected] This page was last updated on 5/28/2020 by MarketBeat.com Staff
